81 related articles for article (PubMed ID: 1948117)
1. Flutamide monotherapy as primary treatment in advanced prostatic carcinoma.
Delaere KP; Van Thillo EL
Semin Oncol; 1991 Oct; 18(5 Suppl 6):13-8. PubMed ID: 1948117
[TBL] [Abstract][Full Text] [Related]
2. A randomized phase II trial of flutamide vs chlormadinone acetate in previously untreated advanced prostatic cancer. The Japan Flutamide Study Group.
Akaza H; Usami M; Kotake T; Koiso K; Aso Y
Jpn J Clin Oncol; 1993 Jun; 23(3):178-85. PubMed ID: 7688829
[TBL] [Abstract][Full Text] [Related]
3. Flutamide versus orchidectomy in the treatment of metastatic prostate carcinoma.
Boccon-Gibod L; Fournier G; Bottet P; Marechal JM; Guiter J; Rischman P; Hubert J; Soret JY; Mangin P; Mallo C; Fraysse CE
Eur Urol; 1997; 32(4):391-5; discussion 395-6. PubMed ID: 9412794
[TBL] [Abstract][Full Text] [Related]
4. The treatment of advanced prostatic carcinoma with total androgenic blockade using bilateral orchidectomy and flutamide: experience at the National Cancer Institute in Mexico.
Mendoza-Valdés A; Ocampo-del-Carpio O; De-la-Garza J
Semin Oncol; 1991 Oct; 18(5 Suppl 6):19-20. PubMed ID: 1948118
[TBL] [Abstract][Full Text] [Related]
5. Combination finasteride and flutamide in advanced carcinoma of the prostate: effective therapy with minimal side effects.
Fleshner NE; Trachtenberg J
J Urol; 1995 Nov; 154(5):1642-5; discussion 1645-6. PubMed ID: 7563310
[TBL] [Abstract][Full Text] [Related]
6. Combined treatment (goserelin plus flutamide) versus monotherapy (goserelin alone) in advanced prostate cancer: a randomized study.
Jurincic CD; Horlbeck R; Klippel KF
Semin Oncol; 1991 Oct; 18(5 Suppl 6):21-5. PubMed ID: 1835139
[TBL] [Abstract][Full Text] [Related]
7. [Clinical evaluation of flutamide, a pure antiandrogen, in prostatic cancer phase II dose-finding study].
Aso Y; Akaza H; Koiso K; Kameyama S; Koyanagi T; Kawai T; Kumamoto Y; Tazaki H; Funyu T; Oshima H
Hinyokika Kiyo; 1993 Apr; 39(4):391-403. PubMed ID: 8503339
[TBL] [Abstract][Full Text] [Related]
8. Characterization of patients with androgen-independent prostatic carcinoma whose serum prostate specific antigen decreased following flutamide withdrawal.
Herrada J; Dieringer P; Logothetis CJ
J Urol; 1996 Feb; 155(2):620-3. PubMed ID: 8558675
[TBL] [Abstract][Full Text] [Related]
9. [Antiandrogens in monotherapy or combined therapy for treatment of advanced cancer of the prostate].
Pavone-Macaluso M; Serretta V; Pavone C; Romano C; Daricello G
Arch Esp Urol; 1989; 42 Suppl 2():197-205. PubMed ID: 2534783
[TBL] [Abstract][Full Text] [Related]
10. Tamoxifen for flutamide/finasteride-induced gynecomastia.
Staiman VR; Lowe FC
Urology; 1997 Dec; 50(6):929-33. PubMed ID: 9426725
[TBL] [Abstract][Full Text] [Related]
11. Intermittent androgen suppression for locally advanced and metastatic prostate cancer: preliminary report of a prospective multicenter study.
Sato N; Akakura K; Isaka S; Nakatsu H; Tanaka M; Ito H; Masai M;
Urology; 2004 Aug; 64(2):341-5. PubMed ID: 15302491
[TBL] [Abstract][Full Text] [Related]
12. PSA evolution: a prognostic factor during treatment of advanced prostatic carcinoma with total androgen blockade. Data from a Belgian multicentric study of 546 patients.
Oosterlinck W; Mattelaer J; Casselman J; Van Velthoven R; Derde MP; Kaufman L
Acta Urol Belg; 1997 Oct; 65(3):63-71. PubMed ID: 9421938
[TBL] [Abstract][Full Text] [Related]
13. Randomized comparison of total androgen blockade alone versus combined with weekly epirubicin in advanced prostate cancer.
Pummer K; Lehnert M; Stettner H; Hubmer G
Eur Urol; 1997; 32 Suppl 3():81-5. PubMed ID: 9267791
[TBL] [Abstract][Full Text] [Related]
14. [Phase I study of flutamide, a nonsteroidal antiandrogen, in patients with prostatic cancer].
Aso Y; Akaza H; Koiso K; Kumamoto Y; Kawai T; Origasa S; Hosaka M; Yamanaka H; Shimazaki J; Fuse H
Hinyokika Kiyo; 1993 Apr; 39(4):381-9. PubMed ID: 8503338
[TBL] [Abstract][Full Text] [Related]
15. Combined androgen blockade in the management of advanced prostate cancer: a sensible or ostensible approach.
Ansari MS; Gupta NP; Hemal AK; Dogra PN; Seth A
Int J Urol; 2004 Dec; 11(12):1092-6. PubMed ID: 15663681
[TBL] [Abstract][Full Text] [Related]
16. Clinical outcome of maximum androgen blockade using flutamide as second-line hormonal therapy for hormone-refractory prostate cancer.
Miyake H; Hara I; Eto H
BJU Int; 2005 Oct; 96(6):791-5. PubMed ID: 16153202
[TBL] [Abstract][Full Text] [Related]
17. Alternative nonsteroidal antiandrogen therapy for advanced prostate cancer that relapsed after initial maximum androgen blockade.
Suzuki H; Okihara K; Miyake H; Fujisawa M; Miyoshi S; Matsumoto T; Fujii M; Takihana Y; Usui T; Matsuda T; Ozono S; Kumon H; Ichikawa T; Miki T;
J Urol; 2008 Sep; 180(3):921-7. PubMed ID: 18635218
[TBL] [Abstract][Full Text] [Related]
18. Epirubicin plus flutamide and orchidectomy in previously untreated advanced prostatic cancer.
Pummer K
Semin Oncol; 1991 Oct; 18(5 Suppl 6):26-8. PubMed ID: 1948120
[TBL] [Abstract][Full Text] [Related]
19. Combined low-dose flutamide plus finasteride vs low-dose flutamide monotherapy for recurrent prostate cancer: a comparative analysis of two phase II trials with a long-term follow-up.
Bañez LL; Blake GW; McLeod DG; Crawford ED; Moul JW
BJU Int; 2009 Aug; 104(3):310-4. PubMed ID: 19239458
[TBL] [Abstract][Full Text] [Related]
20. An implant releasing the gonadotropin hormone-releasing hormone agonist histrelin maintains medical castration for up to 30 months in metastatic prostate cancer.
Chertin B; Spitz IM; Lindenberg T; Algur N; Zer T; Kuzma P; Young AJ; Catane R; Farkas A
J Urol; 2000 Mar; 163(3):838-44. PubMed ID: 10687989
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
